Questions About Gantenerumab Failure Remain, But Roche Is Not Yet Finished With Alzheimer’s
Full Data Presented At CTAD Congress
Roche’s global head of neurodegeneration, Rachelle Doody, talks to Scrip about the failure of gantenerumab and its next-generation ‘brain shuttle’ technology for Alzheimer’s disease.
You may also be interested in...
Drug makers are more enthusiastic than ever about the outlook for developing drugs for Alzheimer's. Scrip reports back on the latest developments at CTAD.
Bill Anderson is leaving Roche after leading its pharma division through the loss of three oncology blockbusters and the launch of a new generation of blood cancer therapies.
Successive waves of Alzhiemer’s therapies are going to be needed, David Ricks said as his company awaits Phase III data on donanemab, the last of three late-stage anti-amyloid drugs to report results.